Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$36.66M$36.66M+112.2% vs Q2 2018 Net Income-$50.22M-$50.22MN/M vs Q2 2018 EPS Diluted-$0.63-$0.63N/M vs Q2 2018 Gross Profit$23,071,000+91.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$23,108,000N/M Free Cash Flowderived-$25,271,000N/M Margins · derivedGross margin62.9%−6.8 pt vs Q2 2018
Operating margin-141.2%+83.6 pt vs Q2 2018
Net margin-137.0%+86.8 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 5, 2019 · 36 d after period end